Abstract 3123
Background
The use of ICTs has become widespread in recent years. There is little information available in Turkey about the level of usage of ICTs for and by cancer patients.
Methods
This descriptive study was conducted to determine the level of ICTs use and patterns of preferences among cancer patients in Ankara, Turkey. The survey was started on March 2019 and the data collection process is continuing. The sample size was determined as 334 and 173 patients were reached. In data collection, a questionnaire including 38 questions about patient demographics, use of cell phones, the interest of patients in using ICTs to receive information about cancer, and the interest of patients in using ICTs to communicate with health care providers about cancer. The study was approved by university research and ethics committees and informed consent were obtained from patients.
Results
The mean age of the participants was 60.19±12.60 (range 27-89 years), 68.2% were female, 45.7% were primary school graduate. Mean duration of diagnosis was 24.12± 28.56 (range 1-120) months, 26% were breast cancer, 21.4 % had metastasis. Of the total, 78.6% of participants reported that they had access to the internet. The ICTs used at least once a week was found to be respectively WhatsApp (63.5%), Facebook (60.7%), instagram (34.1%), youtube (32.3%) and short message service (SMS) text messaging (31.7%). With regard to the preferences on how patients would like to use ICTs to receive information about diseases, Internet (63.0%), SMS (21.3%) and WhatsApp (19.6%) were widely reported as interesting communication channels. Participants 61.8% rely on information obtained through ICTs. Internet (36.4%), SMS (17.3%) followed by WhatsApp (15.0%, 26/173) were reported as the preferred ICTs through which patients would like to ask health providers about diseases. Adjusted regression analysis showed that patients aged between 45-64 years were more likely to be interested in receiving information through SMS than the oldest group.
Conclusions
In this study, we have determined that SMS text messaging presented the highest rate of interest for receiving information and communicating with health providers, followed by WhatsApp.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract